Avricore Health Inc. (TSXV:AVCR,OTCQB:AVCRF) was featured in an article by The Canadian Business Quarterly. Avricore Health is a healthcare technology company focused on health innovation in the nutraceutical, medical cannabis and endocannabinoid industries. The company is focused on looking at how pharmacies and pharmacists currently operate so the company can help identify opportunities to enhance services. With the rise of on-demand retail testing, the company believes that pharmacies can take a more significant role in assisting consumers in making informed healthcare decisions.

Avricore Health is expected to grow as the company works to revolutionize direct-to-consumer healthcare further. To date, Avricore Health has developed HealthTab™, a point-of-care screening system that allows patients to directly measure and monitor the 21 key biomarkers of chronic disease. The system utilizes Abaxis’ Piccolo Xpress® point of care analyzer, which was initially designed by NASA to test the health of astronauts. The company has installed its technology in pharmacies in British Columbia, Alberta and Ontario so far and will be rolling out its technology in up to 200 locations within 18 months.


According to the article, technological innovations are giving shape to pharmacogenomics and how genetics play a role in an individual’s response to drugs. Data from the US Food and Drug Administration (FDA) shows that over 260 therapeutic agents have information on how genes affect them, and this number is expected to grow. The advancements in the pharmacogenomics market are on track to reach $10.2 billion by 2025. Healthcare practitioners are in favor of the trend due to its potential to better serve patients and consumers.

To read the full article, click here.

Click here to connect with Avricore Health Inc. (TSXV:AVCR, OTCQB:AVCRF) for an Investor Presentation. 

As investors continue to prioritize cannabis opportunities in the US, market watchers expect mergers and acquisitions (M&A) to play a role in the future for Canadian companies.

A consolidation trend has been expected in the Canadian cannabis space for some time now based on the size of the market compared to the number of operations in the country.

Keep reading... Show less

The product will include polyphenols known to have significant health benefits.

BioHarvest Sciences Inc. (CSE: BHSC) (“BioHarvest” or the “Company”) has reached an important milestone in its development program of additional Nutraceuticals. The olive-based Nutraceutical product scheduled for market availability in the second half of 2022 will contain the following unique matrix of polyphenols: hydroxytyrosol, trosol, and verbascoside. These compounds are the major polyphenols in naturally grown olives and are responsible for the high antioxidant activity of olives and olive oil. Importantly, the BioHarvest olive-based Nutraceutical product will provide all the benefits of olives and olive oil with a low calorie count per serving.

Keep reading... Show less

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today that it will report financial results for the fourth quarter and full year ended December 31 st , 2020 on Thursday March 25 th , 2021 before the market opens.

The Company will host a conference call and webcast to discuss its financial results and provide investors with key business highlights on Thursday March 25 th , 2021 at 8:30am Eastern Time (7:30am Central Time).

Keep reading... Show less

 Canopy Growth Corporation (TSX: WEED) (NASDAQ: CGC) (“Canopy Growth” or “the Corporation”) announced today that EVP & CFO Mike Lee will be participating in a fireside chat at the BofA Securities Virtual Consumer & Retail Technology Conference on Thursday, March 11, 2021 at 9:30am ET .

Keep reading... Show less

Hill Street Beverage Company Inc. (TSXV: BEER) (“Hill Street” or the “Company”). The Company announces that further to its press release dated March 2, 2021, it has obtained TSX Venture Exchange approval to extend the closing date of its previously announced private placement of units (“Units”) until April 7, 2021. Each Unit is comprised of one (1) common share and one (1) warrant, exercisable for one common share at price of $0.11 per share, for a period of three (3) years from the date of Closing. The Company applied to extend the date of closing to allow a greater number of interested investors to participate.

For more information regarding the Company or the offering, please contact ir@hillstreetbevco.com, or

Keep reading... Show less